However, both classes of drugs are currently enrolling patients in Phase 2 and Phase 3 trials for the treatment of other EGFR positive cancers, such as cervical, skin, myelogenous leukemia, prostate and glioblastomas (ClinicalTrials.gov, 2007). This evidence concerns the gene EGFR and glioblastoma.